Merck and Dyesol Collaborate in Dye Solar Cells

Thu Oct 15, 2009 1:30am EDT

* Reuters is not responsible for the content in this press release.

DARMSTADT, Germany & QUEANBEYAN, Australia--(Business Wire)--
Merck KGaA and Dyesol Limited have signed an agreement to collaborate in the
development of electrolytes for use in Dye Solar Cells (DSC). This joint
development agreement is the precursor to potential future commercial
arrangements with Merck to manufacture existing and next generation electrolytes
for DSC applications like photovoltaic renewable energy sources. 

Merck is one of the world leaders in the development and production of ionic
liquids which are key raw materials used in DSC electrolytes. Merck has patented
intellectual property and vast know-how in the field of ionic liquids. Dyesol,
located in Queanbeyan in New South Wales (Australia), is the leading developer
of DSC materials and solutions, having a broad portfolio covering DSC materials,
product designs and manufacturing equipments. 

The first phase of the collaboration involves the development of new
electrolytes, optimization of electrolytes for high performance, refinement of
material specifications to assure ultra long life, and scale up for volume
manufacture. Dyesol will contribute the results of the past 12 years of testing
on over 400 different proprietary electrolytes that has resulted in DSC with
proven stability of well over 25 years in European conditions. 

"Photovoltaic renewable energy sources are showing increasing potential
worldwide. The cooperation with Dyesol, the world leader in the Dye Solar Cell
sector, offers us the opportunity to leverage valuable potential in this
attractive market," says Dr. Emil Aust, Senior Manager of Ionic Liquids at Merck
KGaA. "When used as the main components of DSC electrolytes, Merck's
task-specific Ionic Liquids, make it possible to use both solid and flexible
DSCs, thus enabling outstanding new applications in the future." 

About Merck KGaA

Merck is a global pharmaceutical and chemical company with total revenues of €
7.6 billion in 2008, a history that began in 1668, and a future shaped by
approximately 33,000 employees in 60 countries. Its success is characterized by
innovations from entrepreneurial employees. Merck's operating activities come
under the umbrella of Merck KGaA, in which the Merck family holds an
approximately 70% interest and free shareholders own the remaining approximately
30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an
independent company ever since. More detail about Merck can be found at:

Merck KGaA
Steffen Grimminger, +49-6151-72-7317 

Copyright Business Wire 2009